Research ArticleArticles

Assessment and Management of Rheumatoid Arthritis

BOULOS HARAOUI
The Journal of Rheumatology Supplement June 2009, 82 2-10; DOI: https://doi.org/10.3899/jrheum.090124

REFERENCES

  1. 1.↵
    1. Felson DT,
    2. Anderson JJ,
    3. Boers M,
    4. et al
    . American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Van Gestel AM,
    2. Prevoo MLL,
    3. van ‘t Hof MA,
    4. van Rijswijk MH,
    5. van de Putte LBA,
    6. van Riel PLCM
    . Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34–40.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. van der Heijde DM,
    2. van ‘t Hof MA,
    3. van Riel PLCM,
    4. van de Putte LBA
    . Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579–81.
    OpenUrlPubMed
  4. 4.↵
    1. Smolen JS,
    2. Breedveld FC,
    3. Schiff MH,
    4. et al
    . A simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244–57.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Aletaha D,
    2. Smolen J
    . The simplified Disease Activity Index (SDAI) and the clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100–8.
    OpenUrlPubMed
  6. 6.↵
    1. Aletaha D,
    2. Funovits J,
    3. Smolen JS
    . Treatment aims in rheumatoid arthritis: response versus state [abstract]. Arthritis Rheum 2007;56 Suppl:S819.
    OpenUrl
  7. 7.↵
    1. Prevoo ML,
    2. van’t Hof MA,
    3. Kuper HH,
    4. van Leeuwen MA,
    5. van de Putte LBA,
    6. van Riel PLCM
    . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Stucki G,
    2. Liang MH,
    3. Stucki S,
    4. Brühlmann P,
    5. Michel BA
    . A self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995;38:795–8.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Saag KG,
    2. Teng GG,
    3. Patkar NM,
    4. et al
    . American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–84.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Landewe R,
    2. Lukas C,
    3. Fatenejad S,
    4. van der Heijde D
    . The disconnect between inflammation and radiographic progression in patients treated with TNF-blocking drugs also exists at the individual joint level [abstract]. Arthritis Rheum 2006;54 Suppl:486.
    OpenUrl
  11. 11.↵
    1. Smolen JS,
    2. Emery P,
    3. Bathon J,
    4. et al
    . Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone: preliminary results of the ASPIRE trial [abstract]. European League Against Rheumatism 2003; Lisbon, Portugal; 18–21 June, 2003: OP0001.
  12. 12.↵
    1. Mierau M,
    2. Schoels M,
    3. Gonda G,
    4. Fuchs J,
    5. Aletaha D,
    6. Smolen JS
    . Assessing remission in clinical practice. Rheumatology 2007;46:975–9.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Combe B,
    2. Landewe R,
    3. Lukas C,
    4. et al
    . EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34–45.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Combe B,
    2. Dougados M,
    3. Goupille P,
    4. et al
    . Prognostic factors for radiographic damage in early rheumatoid arthritis: a multi-parameter prospective study. Arthritis Rheum 2001;44:1736–43.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Visser H,
    2. le Cessie S,
    3. Vos K,
    4. Breedveld FC,
    5. Hazes JM
    . How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357–65.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Smolen JS,
    2. Han C,
    3. van der Heijde D,
    4. et al
    . Infliximab inhibits radiographic progression regardless of disease activity at baseline and following treatment in patients with early active rheumatoid arthritis [abstract]. Arthritis Rheum 2006;54 Suppl:S231.
    OpenUrl
  17. 17.↵
    1. O’Dell JR,
    2. Leff R,
    3. Paulsen G,
    4. et al
    . Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164–70.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Bakker MF,
    2. Jacobs JW,
    3. Verstappen SM,
    4. Bijlsma JW
    . Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66 Suppl 3:iii56–60.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Grigor C,
    2. Capell H,
    3. Stirling A,
    4. et al
    . Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263–9.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Makinen H,
    2. Kautiainen H,
    3. Hannonen P,
    4. et al
    . Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007;34:316–21.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Goekoop-Ruiterman YP,
    2. de Vries-Bouwstra JK,
    3. Allaart CF,
    4. et al
    . Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406–15.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Verstappen SM,
    2. Jacobs JW,
    3. van der Veen MJ,
    4. et al.,
    5. Utrecht Rheumatoid Arthritis Cohort study group
    . Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443–9.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Kuper I,
    2. Hoekstra M,
    3. ten Klooster P,
    4. et al
    . Remission can be achieved in 50% of early rheumatoid arthritis patients after 25 weeks in daily clinical practice [abstract]. Ann Rheum Dis 2008;67 Suppl II:48.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Emery P,
    2. Genovese M,
    3. Van Vollenhoven R,
    4. Patra K,
    5. Sasso E
    . Less progression of joint erosion (JE) and joint space narrowing (JSN) with adalimumab plus MTX vs. MTX monotherapy at all levels of clinical response: subanalysis of PREMIER [abstract]. Ann Rheum Dis 2007;66 Suppl II:169.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Hyrich KL,
    2. Lunt M,
    3. Watson KD,
    4. Symmons DPM,
    5. Silman AJ
    . Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. Arthritis Rheum 2007;56:13–20.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Gomez-Reino JJ,
    2. Carmona L,
    3. BIOBADASER Group
    . Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Navarro F,
    2. Gomez-Reino J,
    3. Marsal S,
    4. et al
    . EULAR response in clinical practice in RA patients treated with one, two or three anti-TNF alpha agents: results of an observational, prospective, cohort study in Spain [abstract]. Arthritis Rheum 2006;54 Suppl:S384.
    OpenUrl
  28. 28.↵
    1. Smolen JS,
    2. Han C,
    3. van der Heijde D,
    4. et al
    . Infliximab inhibits radiographic progression regardless of disease activity at baseline and following treatment in patients with early active rheumatoid arthritis [abstract]. Arthritis Rheum 2006;54 Suppl:S231.
    OpenUrl
  29. 29.↵
    1. Cohen SB,
    2. Emery P,
    3. Greenwald MW,
    4. et al.,
    5. REFLEX Trial Group
    . Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–806.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Kremer JM,
    2. Tony H,
    3. Tak PP,
    4. et al
    . Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors [abstract]. Ann Rheum Dis 2006;65 Suppl II:326.
    OpenUrl
  31. 31.↵
    1. Cohen S,
    2. Keystone E,
    3. Genovese MC,
    4. et al
    . Continued inhibition of structural damage in rheumatoid arthritis patients treated with rituximab at 2 years: REFLEX study [abstract]. Ann Rheum Dis 2008;67 Suppl II:189.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Genovese MC,
    2. Becker JC,
    3. Schiff M,
    4. et al
    . Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114–23.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Genovese MC,
    2. Schiff M,
    3. Luggen M,
    4. et al
    . Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547–54.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Kremer J,
    2. Westhovens R,
    3. Luggen M,
    4. et al
    . Long-term efficacy and safety of abatacept through 3 years of treatment in rheumatoid arthritis patients in the AIM and ATTAIN trials [abstract]. Arthritis Rheum 2007;56 Suppl:S300.
    OpenUrl
  35. 35.↵
    1. Finckh A,
    2. Ciurea A,
    3. Brulhart L,
    4. et al
    . Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417–23.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Visser K,
    2. van der Heijde D
    . Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature [abstract]. Arthritis Rheum 2008;58 Suppl:S311.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section